• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    ALX Oncology Holdings Inc. - Common Stock (NQ:ALXO)

    1.425 +0.055 (+4.01%)
    Streaming Delayed Price Updated: 3:40 PM EST, Dec 5, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 252,516
    Open 1.370
    Bid (Size) 1.420 (200)
    Ask (Size) 1.430 (400)
    Prev. Close 1.370
    Today's Range 1.370 - 1.480
    52wk Range 0.4040 - 2.270
    Shares Outstanding 40,869,135
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
    EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:ALXO),(NASDAQ:ERAS),(NASDAQ:IMRX),(NASDAQ:PRLD) EQNX::TICKER_END 
    Via FinancialNewsMedia
    News headline image
    Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
    From FN Media Group LLC
    Via GlobeNewswire

    Performance

    YTD
    -8.7%
    -8.7%
    1 Month
    -2.4%
    -2.4%
    3 Month
    +31.9%
    +31.9%
    6 Month
    +171.4%
    +171.4%
    1 Year
    -8.7%
    -8.7%

    More News

    Read More
    News headline image
    ALX Oncology to Present at Upcoming Investor Conferences
    From ALX Oncology
    Via GlobeNewswire
    News headline image
    ALX Oncology Holdings Inc (NASDAQ:ALXO) Reports Wider-Than-Expected Q3 2025 Loss Amid Promising Clinical Data ↗
    Via Chartmill
    News headline image
    ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update
    From ALX Oncology
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For November 7, 2025 ↗
    Via Benzinga
    News headline image
    Examining the Future: ALX Oncology Holdings's Earnings Outlook ↗
    Via Benzinga
    News headline image
    ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting
    From ALX Oncology
    Via GlobeNewswire
    News headline image
    ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
    From ALX Oncology
    Via GlobeNewswire
    News headline image
    ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
    From ALX Oncology
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Monday's After-Market Session ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Friday's Intraday Session ↗
    Via Benzinga
    News headline image
    Which stocks are gapping on Friday? ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Thursday's After-Market Session ↗
    Via Benzinga
    News headline image
    Stay updated with the stocks that are on the move in today's after-hours session. ↗
    Via Chartmill
    News headline image
    ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer
    From ALX Oncology
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
    Via Benzinga
    News headline image
    ALX Oncology to Participate in Upcoming Investor Conferences in September
    From ALX Oncology
    Via GlobeNewswire
    News headline image
    Unusual volume stocks in Friday's session ↗
    Via Chartmill
    News headline image
    Tuesday's pre-market session: top gainers and losers ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Why Palo Alto Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket ↗
    Via Benzinga
    News headline image
    ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors
    From ALX Oncology
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Monday's After-Market Session ↗
    Via Benzinga
    News headline image
    Curious about the stocks that are showing activity after the closing bell on Monday? ↗
    Via Chartmill

    Frequently Asked Questions

    Is ALX Oncology Holdings Inc. - Common Stock publicly traded?
    Yes, ALX Oncology Holdings Inc. - Common Stock is publicly traded.
    What exchange does ALX Oncology Holdings Inc. - Common Stock trade on?
    ALX Oncology Holdings Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for ALX Oncology Holdings Inc. - Common Stock?
    The ticker symbol for ALX Oncology Holdings Inc. - Common Stock is ALXO on the Nasdaq Stock Market
    What is the current price of ALX Oncology Holdings Inc. - Common Stock?
    The current price of ALX Oncology Holdings Inc. - Common Stock is 1.425
    When was ALX Oncology Holdings Inc. - Common Stock last traded?
    The last trade of ALX Oncology Holdings Inc. - Common Stock was at 12/05/25 03:40 PM ET
    What is the market capitalization of ALX Oncology Holdings Inc. - Common Stock?
    The market capitalization of ALX Oncology Holdings Inc. - Common Stock is 58.24M
    How many shares of ALX Oncology Holdings Inc. - Common Stock are outstanding?
    ALX Oncology Holdings Inc. - Common Stock has 58M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.